Role of endothelial progenitor cells during ischemia-induced vasculogenesis and collateral formation.
Cell-based therapy has emerged as a promising therapeutic tool for treatment of ischemic cardiovascular disease. Both unselected bone marrow-derived mononuclear cells (BMNCs), which include stem/progenitor cells and several other cell types, and endothelial progenitor cells (EPCs), a subpopulation of BMNCs, display regenerative potential in ischemic tissue. Abundant evidence supports the involvement of EPCs in capillary growth, and EPCs also appear to participate in the formation of collateral vessels. Collectively, these effects have led to improved perfusion and functional recovery in animal models of myocardial and peripheral ischemia, and in early clinical trials, the therapeutic administration of EPCs to patients with myocardial infarction or chronic angina has been associated with positive trends in perfusion. EPCs also contribute to endothelial repair and may, consequently, impede the development or progression of arteriosclerosis. This review provides a brief summary of the preclinical and clinical evidence for the role of EPCs in blood-vessel formation and repair during ischemic cardiovascular disease.
Feinberg Cardiovascular Research Institute, Northwestern University, Tarry 12-703, 303 East Chicago Avenue, Chicago, IL 60611, USA.
Jörn
J
Tongers
Jerome G
JG
Roncalli
Douglas W
DW
Losordo
D000818:Animals; D003097:Collateral Circulation; D042783:Endothelial Cells / Q000473:pathology / Q000637:transplantation; D004730:Endothelium, Vascular / Q000473:pathology / Q000503:physiopathology*; D006801:Humans; D007511:Ischemia / Q000473:pathology / Q000503:physiopathology* / Q000601:surgery; D018919:Neovascularization, Physiologic; D012038:Regeneration; D033581:Stem Cell Transplantation; D013234:Stem Cells / Q000473:pathology